// App-Quantinova.ai

385 : A phase Ib/IIa study of combination therapy with gemcitabine and Atu027 in patients with locally advanced or metastatic pancreatic adenocarcinoma.

Researchers

Presenter

  • Beate Schultheis

Principal Investigators

  • Dirk Strumberg

  • Jan Kuhlmann

  • Martin Wolf

  • Karin Link

  • Thomas Seufferlein

  • Joerg Kaufmann

  • Frank Gebhardt

  • Nico Bruyniks

  • Uwe Pelzer

Medical Centers

  • Department of Hematology and Oncology, Marien Hospital Herne, University of Bochum, Herne, Germany

  • Department of Medicine II, University Hospital Freiburg, Freiburg, Germany

  • Klinikum Kassel, Kassel, Germany

  • Klinikum Nuernberg Nord, Med. Klinik 5, Onkologie, Nuernberg, Germany

  • Universitatsklinikum Ulm, Klinik fur Innere Medizin I, Ulm, Ulm, Germany

  • Silence Therapeutics AG, Berlin, Germany

  • Brinphar Limited, Iver Heath, United Kingdom

  • Medical Oncology, CONKO Study Group, Charité-Universitätsmedizin Berlin, Berlin, Germany

Locations

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Metastatic pancreatic adenocarcinoma

Biomarkers

  • Adenomatous Polyposis Coli

Drug/Treatment

  • Gemcitabine

  • Atu-027

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01808638

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved